MIAMI, May 13, 2024
/PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical
development company pioneering transformative therapies for
autoimmune and post-viral illnesses, today announced the
publication of its phase 2 long COVID results in Clinical
Infectious Diseases. The publication entitled "Assessment of
the Impact of RNase in Patients with Severe Fatigue Related to
Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A randomized
phase 2 trial of RSLV-132" evaluated the impact of RNase in one
hundred and eight patients diagnosed with COVID-19 at least 6
months prior to baseline and with a history of continuous, severe
fatigue. Participants received 6 doses of RSLV-132 or placebo over
two months. The study measured fatigue and overall disease activity
using the PROMIS SF 10a, FACIT-Fatigue, and physician's global
assessment.
Approximately 18 million Americans suffer the debilitating
effects of long COVID. The most common symptoms are extreme
fatigue, brain fog, immune dysregulation and depression or
anxiety. Despite the large unmet medical need, A recent editorial
in The Lancet identified only 12 pharmacological
interventional clinical trials in development. Thus, very little
progress has been made towards identifying drugs to treat the
cardinal symptoms of long COVID. RSLV-132 has demonstrated
significant clinical activity in improving autoimmune-related
fatigue in Sjogren's syndrome. Results from the current long COVID
phase 2 study suggest patients suffering from long COVID may also
benefit from the removal of circulating RNA.
"We are encouraged by the potential for RSLV-132 to improve the
debilitating fatigue suffered by so many long COVID patients"
commented Dr. James Posada chief
executive officer of Resolve Therapeutics. "Interestingly, our data
further suggests that women may respond better to RSLV-132 and
digestion of latent viral RNA than men" added Dr. Posada.
About RSLV-132
RSLV-132 is
a non-immunosuppressive, biologic drug comprised of
catalytically active human RNase1 fused to the Fc region of human
IgG1. It is designed to remain in serum circulation and digest
extracellular pathogenic RNA. RNA is the primary trigger of
interferon and cytokine production that drives chronic
inflammation in diseases such as SLE, Sjogren's. Recent studies
suggest that RNA may play a role in post-viral illnesses such as
PASC and ME/CFS as well. Therefore, removing it from circulation
may decrease inflammation and improve the symptoms associated with
these diseases.
About Resolve Therapeutics
Resolve is a private
biotech company pioneering a transformative approach to autoimmune
and post-viral diseases. The company is leveraging the extensive
body of scientific discoveries that demonstrate the central role of
pathogenic RNA molecules, weather self-derived or from viral
sources, in driving inflammatory and neuroinflammatory symptoms.
Resolve is actively developing RSLV-132 in mid-stage clinical
development programs including SLE, Sjogren's syndrome, and
post-acute sequelae of SARS-CoV-2 infection (PASC). For more
information please
visit: https://resolvetherapeutics.com/
Contact:
James
Posada
Resolve Therapeutics
208-727-7010
jp@resolvebio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/resolve-therapeutics-publishes-results-of-rslv-132-phase-2-long-covid-study-302143453.html
SOURCE Resolve Therapeutics, LLC